Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
Corcept Therapeutics (NASDAQ:CORT) Inc NASDAQ: CORT Chief Executive Officer Joseph K. Belanoff, through a revocable living trust, sold a total of 39,990 shares of common stock on August 1, 2025, in three separate transactions. The sales amounted to approximately $2.74 million in the $7.42 billion market cap company, which has seen its stock surge 104% over the past year according to InvestingPro data.
The shares were sold at weighted average prices ranging from $67.8063 to $69.6483. Specifically, 16,745 shares were sold at an average price of $67.8063, 17,809 shares were sold at an average price of $68.8689, and 5,446 shares were sold at an average price of $69.6483. The price range for the sales was between $67.42 and $69.77.
Following the transactions, the trust’s holdings in Corcept Therapeutics common stock totaled 2,861,370 shares.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Belanoff on November 26, 2024.
In other recent news, Corcept Therapeutics announced its Q2 2025 financial results, which revealed a mixed performance. The company reported an earnings per share (EPS) of $0.29, surpassing the forecasted $0.19 by 52.63%. This significant EPS beat was overshadowed by a slight revenue miss, as Corcept posted $194.4 million in revenue compared to the anticipated $199.4 million, marking a 2.51% shortfall. Despite the positive earnings, the revenue miss was attributed to ongoing supply chain issues. These recent developments have drawn investor attention as they assess the company’s financial health. Analysts continue to monitor Corcept’s performance in light of these results. The company’s ability to address supply chain challenges remains a focal point for stakeholders. Such financial outcomes are crucial for investors making informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.